J Dent Anesth Pain Med.  2017 Jun;17(2):157-161. 10.17245/jdapm.2017.17.2.157.

Managing the behavior of a patient with autism by sedation via submucosal route during dental treatment

• Jo CW
• Park CH
• Lee JH
• Kim JH

• KMID: 2384479
• DOI: http://doi.org/10.17245/jdapm.2017.17.2.157

Abstract

In sedation via the submucosal route, the drug is administered through the maxillary buccal submucosa. It is time saving, effective, and safe. Patients with autism, a mental disorder, often find it hard to make relationships with other people. These patients display a strong resistance to dental treatment and sedation. This study reports a successful case of behavioral management during dental treatment, using sedation via the submucosal route. The patient was strongly resistant to sedation via the oral, intramuscular, and intravenous routes. The drug used was 9 mg (0.1 mg/kg) of midazolam. Through this case report, we reaffirm the significance of sedation via the submucosal route, and expect that it will be used more frequently for patients with autism, who display behaviors that are difficult to manage, patients with other disabilities, and children.

Keyword

Autism; Behavior; Management; Sedation; Submucosal Route

MeSH Terms

Autistic Disorder*
Child
Humans
Mental Disorders
Midazolam
Midazolam

Figure

• 

  Fig. 1 Flow chart of the case is presented. The patient with autism whose behavior could not be managed was quickly and sufficiently sedated via the submucosal route in a situation where sedation was not possible through other routes.

Reference

1. Moore PA, Mickey EA, Hargreaves JA, Needleman HL. Sedation in pediatric dentistry: a practical assessment procedure. J Am Dent Assoc. 1984; 109:564–569.

2. Runes J, Ström C. Midazolam intravenous conscious sedation in oral surgery. A retrospective study of 372 cases. Swed Dent J. 1996; 20:29–33.

3. Rapin I, Tuchman RF. Autism: definition, neurobiology, screening, diagnosis. Pediatr Clin North Am. 2008; 55:1129–1146.

4. Braff MH, Nealon L. Sedation of the autistic patient for dental procedures. ASDC J Dent Child. 1979; 46:404–407.

5. Baek K. Considerations for submucosal midazolam administration in combination with oral and inhaled medications for sedation of pediatric dental patients. J Dent Anesth Pain Med. 2015; 15:47–52.

6. Alfonzo-Echeverri E, Troutman KC, George W. Absorption and elimination of midazolam by submucosal and intramuscular routes. Anesth Prog. 1990; 37:277–281.

7. Lee YE, Park MK, Kim YH, Jung SH, Baek KW. The sedative effects of submucosal midazolam in children. J Korean Dent Soc Anesthesiol. 2005; 5:101–106.

8. Song YU, Webb MD. Comparison of the effect of orally versus submucosally administered meperidine on the behavior of pediatric dental patients: a retrospective study. Anesth Prog. 2003; 50:129–133.

9. Thummel KE, O'shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Thera. 1996; 59:491–502.

10. Trapp LD, Goodson JM, Price DC. Evaluation of oral submucosal blood flow at dental injection sites by radioactive xenon clearance in beagle dogs. J Dent Res. 1977; 56:889–893.

11. Hine CH, Pasi A. Fatality after use of alphaprodine in analgesia for dental surgery: report of case. J Am Dent Assoc. 1972; 84:858–861.

12. Azevedo ID, Ferreira MAF, da Costa APS, Bosco VL, Moritz RD. Efficacy and safety of midazolam for sedation in pediatric dentistry: a controlled clinical trial. J Dent Child (Chic). 2013; 80:133–138.

13. Brogden RN, Goa KL. Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs. 1991; 42:1061–1089.

14. Whitwam JG, Amrein R. Pharmacology of flumazenil. Acta Anaesthesiol Scand Suppl. 1995; 108:3–14.

15. Schmitt M, Nazif MM, McKee KC, Zullo T, Venkataramanan R, Burckart G, et al. Pharmacokinetics and local responses to submucosal meperidine compared with other routes of administration. Pediatr Dent. 1994; 16:190–192.

16. Pisalchaiyong T, Trairatvorakul C, Jirakijja J, Yuktarnonda W. Comparison of the effectiveness of oral diazepam and midazolam for the sedation of autistic patients during dental treatment. Pediatr Dent. 2005; 27:198–206.

17. Myers GR, Maestrello CL, Mourino AP, Best AM. Effect of submucosal midazolam on behavior and physiologic response when combined with oral chloral hydrate and nitrous oxide sedation. Pediatr Dent. 2004; 26:37–43.